Neuropathies in the context of malignancies

Current Opinion in Neurology

Volumn 21, Issue 5, 2008, Pages 534-539

  Behin, Anthony ^a   Psimaras, Dimitri ^b   Hoang Xuan, Khe ^b   Leger, Jean Marc ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Chemotherapy; Dropped head syndrome; Neurolymphoma; Neuropathy; Paraneoplastic syndrome; Radiotherapy

Indexed keywords

ANTIOXIDANT; BORTEZOMIB; CALCIUM; CARBAMAZEPINE; CARBOPLATIN; CHELATING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GLUTAMINE; GLUTATHIONE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; MAGNESIUM; NAVELBINE; OXALIPLATIN; OXCARBAZEPINE; PACLITAXEL; PLACEBO; STEROID; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE; XALIPRODEN;

ATAXIA; AUTONOMIC DYSFUNCTION; AUTONOMIC NEUROPATHY; BALANCE IMPAIRMENT; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLD INDUCED DYSESTHESIA; COLON CANCER; DEMYELINATING NEUROPATHY; DOSAGE SCHEDULE COMPARISON; DROP HEAD SYNDROME; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSESTHESIA; HODGKIN DISEASE; HUMAN; JAW CONTRACTURE; LHERMITTE DUCLOS DISEASE; LIMB PARESTHESIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MONONEUROPATHY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE ATROPHY; MUSCLE CRAMP; MUSCLE WEAKNESS; NECK INJURY; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; PAIN; PARANEOPLASTIC NEUROPATHY; PARESTHESIA; PERIORAL PARESTHESIA; PERIPHERAL AXONAL NEUROPATHY; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; RADICULOPATHY; REVIEW; SENSORY NEUROPATHY; TONGUE PARESTHESIA; VASCULITIS; WEAKNESS;

EID: 53549109425     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32830f226d     Document Type: Review

References (41)

1. Behin A, Delattre JY. Complications of radiation therapy on the brain and spinal cord. Semin Neurol 2004; 24:405-417.
2. Viala K, Behin A, Maisonobe T, et al. Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg PsycNatry 2008; 79:778-782. This study gives an overview of the neurologic complications of tymphoma in a large cohort of unselected patients.
3. Zivkovic SA, Ascherman D, Lacomis D. Vasculitic neuropathy- electrodiagnostic findings and association with malignancies. Acta Neurol Scand 2007; 115:432-436.
4. Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 2007; 57:1473-1480. This retrospective study conducted by a group of leading French internal medicine teams places neuropathy in the perspective of the numerous other complications of vasculitides.
5. Vedeler CA, Antoine JC, Giometto B, et al., Paraneoplastic Neurological Syndrome Euronetwork. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006; 13:682-690.
6. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75:1135-1140.
7. Graus F, Keime-Guibert F, Reoe R, et al. Anti-Hu associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124:1138-1148.
8. Oki Y, Koike H, lijima M, et al. Ataxic vs painful form of paraneoplastic neuropathy. Neurology 2007; 68:564-572.
9. Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol 2007; 20:719-725.
10. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13:27-46. This remarkable review gives the most updated overview of the peripheral neurotoxicity of chemotherapy to date.
11. Krarup-Hansen A, Hetweg-Larsen S, Schmalbruch H, et al. Neuronal involvemerit in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007; 130:1076-1088. An elegant demonstration of the primary location of the neurotoxic lesions induced by cisplatin.
12. Argyriou AA, Polychronopoulos P, lconomou G, et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol 2007; 46:1131-1137.
13. Argyriou AA, Polychronopouloss P, Iconomou G, et al. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008; 34:368-377. Remarkable overview of acquired data on this widely used chemotherapy agent
14. Lecomte T, Landi B, Beaune P, et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12:3050-3056.
15. Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 2005; 1:249-258.
16. von Delius S, Eckel F, Wagenpfeil S, et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 2007; 25:173-180.
17. Argyriou AA, Chroni E, Polychronopoulos P, et al. Efficacy of oxcarbazepine. Neurology 2006; 67:2253-2255.
18. Wang WS, Lin JK, Lin TC, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007; 12:312-319.
19. Gibson TB, Ranganathan A, D'Orazio A. Highlights from the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium San Francisco, CA, January 2006. Clin Colorectal Cancer 2006; 5:398-402.
20. Gamelin L, Boisdron-Celle M, Delva R. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004; 10: 4055-4061.
21. André T, Tournigand C, Mineur L, et al. Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with cetecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol 2007; 18:77-81.
22. Petrioli R, Paolelli L, Marsili S, et al. FOLFOX-4stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. Oncology 2006; 70:345-350.
23. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006; 24: 394-400.
24. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nano-particle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794-7803.
25. Hattori Y, Okamoto SI, Shimada N, et al. Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: prognostic factors and unique toxicity profile. Cancer Sci 2008; 99:1243-1250.
26. Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006; 24:4507-4514.
27. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108:3458-3464.
28. Dimopoulos M, Spencer A, Attal M, et al., Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357:2123-2132.
29. Badros A, Golubeva O, Dalai JS. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007; 110:1042-1049.
30. Cavaletti G, Nobile-Orazio E. Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 2007; 92:1308-1310.
31. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24:3113-3120.
32. Poruchynsky MS, Sackett DL, Robey RW, et al. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 2008; 7:940-949.
33. Cavaletti G, Frigeni B, Lanzani F, et al. The total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity scale. J Peripher Nerv Syst 2007; 12:210-215. A major step in the validation of TNS as an important and accurate evaluation tool for cancer neuropathies.
34. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003; 61:1297-1300.
35. Cavaletti G, Bogliun G, Marzorati L, et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol 2004; 15:1439-1442.
36. Cavaletti G, Jann S, Pace A, et al. Multicenter assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 2006; 11:135-141.
37. Hughes R. NCI-CTC vs TNS: which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy? Nat Clin Pract Neural 2008; 4:68-69.
38. Johansson AS, Erlanson M, Lenner P, et al. Late side-effects are common after treatment of Hodgkin's disease. Muscular atrophy following radiotherapy is a neglected risk. Lakartidningen 1998; 95:44-47.
39. Aggarwal S, Amato A. Radiation induced myopathy following mantle field radiation for Hodgkin's disease: a report of 4 cases [abstract; P05.107]. Neurology 2007 (Suppl 1).
40. Rowin J, Cheng G, Lewis SL, et al. Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease. Muscle Nerve 2006; 34:666-669.
41. Bowen J, Gregory R, Squier M, Donaghy M. The postirradiation lower motor neuron syndrome neuronopathy or radiculopathy? Brain 1996; 119:1429-1439.